Should I buy or sell BIOLASE stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BIOL shares. View BIOL analyst ratings or view top-rated stocks .

What is BIOLASE's stock price target for 2024?

2 Wall Street analysts have issued 12-month price targets for BIOLASE's stock. Their BIOL share price targets range from $4.00 to $150.00. On average, they anticipate the company's share price to reach $77.00 in the next twelve months. This suggests a possible upside of 4,999.3% from the stock's current price. View analysts price targets for BIOL or view top-rated stocks among Wall Street analysts .

How have BIOL shares performed in 2023?

BIOLASE's stock was trading at $65.00 on January 1st, 2023. Since then, BIOL stock has decreased by 97.7% and is now trading at $1.51. View the best growth stocks for 2023 here .

Are investors shorting BIOLASE?

BIOLASE saw a increase in short interest in November. As of November 15th, there was short interest totaling 100,500 shares, an increase of 1,068.6% from the October 31st total of 8,600 shares. Based on an average trading volume of 309,600 shares, the days-to-cover ratio is currently 0.3 days. Approximately 5.1% of the shares of the stock are short sold. View BIOLASE's Short Interest .

When is BIOLASE's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our BIOL earnings forecast .

How were BIOLASE's earnings last quarter?

BIOLASE, Inc. (NASDAQ:BIOL) released its quarterly earnings results on Thursday, November, 9th. The medical technology company reported ($3.89) earnings per share (EPS) for the quarter. The medical technology company earned $10.92 million during the quarter. BIOLASE had a negative trailing twelve-month return on equity of 503.34% and a negative net margin of 50.61%.

When did BIOLASE's stock split?

BIOLASE's stock reverse split on Friday, July 28th 2023. The 1-100 reverse split was announced on Friday, July 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What is John R. Beaver's approval rating as BIOLASE's CEO?

4 employees have rated BIOLASE Chief Executive Officer John R. Beaver on Glassdoor.com . John R. Beaver has an approval rating of 13% among the company's employees. This puts John R. Beaver in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 35.0% of employees surveyed would recommend working at BIOLASE to a friend.

What other stocks do shareholders of BIOLASE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX) , Accelerate Diagnostics (AXDX) , Biocept (BIOC) , Magnachip Semiconductor (MX) , Fluidigm (FLDM) , Matinas BioPharma (MTNB) , MicroVision (MVIS) , Acasti Pharma (ACST) , Bionano Genomics (BNGO) and Genius Brands International (GNUS) .

Who are BIOLASE's major shareholders?

BIOLASE's stock is owned by many different institutional and retail investors. Top institutional shareholders include Walleye Capital LLC (0.74%). Insiders that own company stock include Education Foundation Schuler, John R Beaver, John R Beaver and Jonathan T Md Lord . View institutional ownership trends .

How do I buy shares of BIOLASE?

Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

BIOLASE Stock Price, News & Analysis (NASDAQ:BIOL)

$1.51

+0.36 (+31.30%)

(As of 12/4/2023 ET)

Compare

Today's Range: $1.19
▼
$1.65
50-Day Range: $1.09
▼
$1.89
52-Week Range: $1.07
▼
$88.66

Volume: 2.25 million shs
Average Volume: 165,936 shs
Market Capitalization: $3.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $77.00

BIOLASE MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 4,999.3% Upside
$77.00 Price Target
Short Interest: Bearish
5.10% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.18
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
BIOLASE has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $77.00, BIOLASE has a forecasted upside of 4,999.3% from its current price of $1.51.
Amount of Analyst Coverage
BIOLASE has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.10% of the float of BIOLASE has been sold short.
Short Interest Ratio / Days to Cover
BIOLASE has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in BIOLASE has recently increased by 1,068.60%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
BIOLASE does not currently pay a dividend.
Dividend Growth
BIOLASE does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BIOL.

2.3

News and Social Media Coverage

News Sentiment
BIOLASE has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for BIOLASE this week, compared to 1 article on an average week.
Search Interest
5 people have searched for BIOL on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added BIOLASE to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BIOLASE insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.27% of the stock of BIOLASE is held by insiders.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of BIOLASE is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BIOLASE is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BIOLASE has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BIOLASE Stock (NASDAQ:BIOL)

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, therapy pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.

BIOL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BIOL Stock News Headlines

November 30, 2023 | americanbankingnews.com

BIOLASE (NASDAQ:BIOL) Lowered to "Sell" at StockNews.com

November 15, 2023 | markets.businessinsider.com

Positive Clinical Trial Results and Successful Cost Optimization Initiatives Bolster Buy Rating for Biolase Despite Lowered Price Target

December 5, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 10, 2023 | markets.businessinsider.com

Positive McGuire Study Results Boost Biolase’s Market Potential and Justify Buy Rating

November 10, 2023 | msn.com

Biolase, Adaptive Biotechnologies among healthcare movers

November 9, 2023 | msn.com

Biolase GAAP EPS of -$3.89 misses by $2.04, revenue of $10.92M misses by $2.29M

November 9, 2023 | finance.yahoo.com

BIOLASE REPORTS THIRD QUARTER FINANCIAL RESULTS; COMPANY BENEFITTING FROM STRATEGIC ACTIONS TAKEN TO STREAMLINE OPERATIONS AND GAIN GREATER OPERATIONAL EFFICIENCIES

November 8, 2023 | benzinga.com

A Preview Of Biolase's Earnings

December 5, 2023 | Edge On The Street (Ad)

U.S. Military Defense Fails Without Vanadium?

The metal vanadium is needed for numerous military applications, including jet engines, airframes, and ballistic missiles. And although the U.S. Govt. considers vanadium critical to national security, less than 5% of the metal is mined in America. This means we're at the mercy of China and Russia for our supply.

November 8, 2023 | finance.yahoo.com

Landmark Study Performed by the Independent McGuire Institute Confirms Positive 12 Month Clinical Outcomes for BIOLASE REPAIR® Perio Protocol

November 7, 2023 | finance.yahoo.com

BIOLASE TO REPORT THIRD QUARTER 2023 RESULTS ON NOVEMBER 9, 2023

November 1, 2023 | morningstar.com

Biolase Inc BIOL

October 18, 2023 | ca.finance.yahoo.com

BIOLASE, Inc. (BIOL)

September 18, 2023 | finance.yahoo.com

BIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants

September 15, 2023 | benzinga.com

Here's Why BIOLASE Shares Were Volatile This Week

September 14, 2023 | benzinga.com

Why BIOLASE Stock Is Getting Obliterated Thursday

September 14, 2023 | msn.com

BIOLASE down 30%, prices $4.5M stock offering

September 14, 2023 | marketwatch.com

Biolase Shares Plummet After Offering Prices

September 13, 2023 | finance.yahoo.com

BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants

August 11, 2023 | finanznachrichten.de

BIOLASE, Inc.: Biolase Reports Record Consumable Sales As Total Second Quarter Revenue Increases 17% Year Over Year

August 11, 2023 | finance.yahoo.com

Q2 2023 BIOLASE Inc Earnings Call

August 11, 2023 | msn.com

Biolase Non-GAAP EPS of -$4.24 beats by $1.76, revenue of $14.3M misses by $1.06M

August 11, 2023 | sfgate.com

Biolase: Q2 Earnings Snapshot

August 11, 2023 | finance.yahoo.com

BIOLASE REPORTS RECORD CONSUMABLE SALES AS TOTAL SECOND QUARTER REVENUE INCREASES 17% YEAR OVER YEAR

August 10, 2023 | finance.yahoo.com

BIOLASE, Inc. (BIOL) Interactive Stock Chart - Yahoo Finance

August 9, 2023 | markets.businessinsider.com

Here's what Wall Street expects from Biolase's earnings report

August 3, 2023 | finance.yahoo.com

BIOLASE TO REPORT SECOND QUARTER 2023 RESULTS ON AUGUST 10, 2023

See More Headlines

Receive BIOL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/05/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Dental equipment & supplies
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BIOL
Previous Symbol: NASDAQ:BLTI
CUSIP: N/A
CIK: 811240
Web: www.biolase.com
Phone: (949) 361-1200
Fax: 949-273-6677
Employees: 188
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $77.00
High Stock Price Target: $150.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +4,999.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($158.82)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-28,630,000.00
Net Margins: -50.61%
Pretax Margin: -50.34%
Return on Equity: -503.34%
Return on Assets: -63.51%

Debt

Debt-to-Equity Ratio: 34.06
Current Ratio: 1.40
Quick Ratio: 0.71

Sales & Book Value

Annual Sales: $48.46 million
Price / Sales: 0.07
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $63.32 per share
Price / Book: 0.02

Miscellaneous

Outstanding Shares: 2,300,000
Free Float: 2,291,000
Market Cap: $3.47 million
Optionable: Not Optionable
Beta: 1.16

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. John R. Beaver (Age 62)
President, CEO & Director
Comp: $592.47k
Ms. Jennifer Bright (Age 51)
Chief Financial Officer
Comp: $351.06k
Mr. Steven Sandor (Age 42)
Chief Operating Officer
Comp: $299.43k
Dr. Russell Morrow D.D.S.
Chief Dental Officer
Mr. Michael C. Carroll (Age 51)
Corporate Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BIOL Stock Analysis - Frequently Asked Questions

Should I buy or sell BIOLASE stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BIOL shares.
View BIOL analyst ratings or view top-rated stocks.
What is BIOLASE's stock price target for 2024?: 2 Wall Street analysts have issued 12-month price targets for BIOLASE's stock. Their BIOL share price targets range from $4.00 to $150.00. On average, they anticipate the company's share price to reach $77.00 in the next twelve months. This suggests a possible upside of 4,999.3% from the stock's current price.
View analysts price targets for BIOL or view top-rated stocks among Wall Street analysts.
How have BIOL shares performed in 2023?: BIOLASE's stock was trading at $65.00 on January 1st, 2023. Since then, BIOL stock has decreased by 97.7% and is now trading at $1.51.
View the best growth stocks for 2023 here.
Are investors shorting BIOLASE?: BIOLASE saw a increase in short interest in November. As of November 15th, there was short interest totaling 100,500 shares, an increase of 1,068.6% from the October 31st total of 8,600 shares. Based on an average trading volume of 309,600 shares, the days-to-cover ratio is currently 0.3 days. Approximately 5.1% of the shares of the stock are short sold.
View BIOLASE's Short Interest.
When is BIOLASE's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our BIOL earnings forecast.
How were BIOLASE's earnings last quarter?: BIOLASE, Inc. (NASDAQ:BIOL) released its quarterly earnings results on Thursday, November, 9th. The medical technology company reported ($3.89) earnings per share (EPS) for the quarter. The medical technology company earned $10.92 million during the quarter. BIOLASE had a negative trailing twelve-month return on equity of 503.34% and a negative net margin of 50.61%.

When did BIOLASE's stock split?: BIOLASE's stock reverse split on Friday, July 28th 2023. The 1-100 reverse split was announced on Friday, July 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.
What is John R. Beaver's approval rating as BIOLASE's CEO?: 4 employees have rated BIOLASE Chief Executive Officer John R. Beaver on Glassdoor.com. John R. Beaver has an approval rating of 13% among the company's employees. This puts John R. Beaver in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 35.0% of employees surveyed would recommend working at BIOLASE to a friend.
What other stocks do shareholders of BIOLASE own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Biocept (BIOC), Magnachip Semiconductor (MX), Fluidigm (FLDM), Matinas BioPharma (MTNB), MicroVision (MVIS), Acasti Pharma (ACST), Bionano Genomics (BNGO) and Genius Brands International (GNUS).
Who are BIOLASE's major shareholders?: BIOLASE's stock is owned by many different institutional and retail investors. Top institutional shareholders include Walleye Capital LLC (0.74%). Insiders that own company stock include Education Foundation Schuler, John R Beaver, John R Beaver and Jonathan T Md Lord.
View institutional ownership trends.
How do I buy shares of BIOLASE?: Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BIOL) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial